Analytical Data
-
Gene name
TCEAL7
- Application
-
Alternative Names
TCEAL7；Transcription elongation factor A Protein-like 7
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BRU2
-
Expression Region
1-100aa
-
AA Sequence
MQKPCKENEG KPKCSVPKRE EKRPYGEFER QQTEGNFRQR LLQSLEEFKE DIDYRHFKDE EMTREGDEME RCLEEIRGLR KKFRALHSNH RHSRDRPYPI
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TCEAL7, a member of the T-cell-specific transcriptional regulator (TCEAL) family, plays a critical role in regulating gene expression and has been implicated in various biological processes, including immune response and cellular differentiation. The interest in TCEAL7 research has increased due to its potential involvement in cancer progression and other diseases. For example, studies have indicated that TCEAL7 may influence the activation of T cells, affecting their ability to mount an effective immune response. Additionally, alterations in the expression of TCEAL7 have been linked to various types of cancers, suggesting it could serve as a biomarker for tumor progression or a target for therapeutic intervention. Understanding the molecular mechanisms by which TCEAL7 exerts its effects is crucial for developing novel strategies in immunotherapy and other treatment modalities. Consequently, there is an urgent need for research focused on the recombinant expression, purification, and functional characterization of TCEAL7 to elucidate its roles and mechanisms in disease contexts. This research could pave the way for innovative approaches in the prevention and treatment of immune-related disorders and malignancies, highlighting the significance of TCEAL7 in both basic and applied biomedical research.
